Evidence map›Paper›PMID 35936013›Full record

ArticleFrontiers in immunology2022

Low-dose mycophenolate mofetil improves survival in a murine model of

Fanny Alby-Laurent, Nadia Belaïdouni, Benoit Blanchet, Christophe Rousseau, Jean-François Llitjos, Sylvia Sanquer, Jean-Paul Mira, Frédéric Pène, Julie Toubiana, Jean-Daniel Chiche

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Fanny Alby-LaurentCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Nadia BelaïdouniCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Benoit BlanchetDepartment of Pharmocology and Toxicology, Cochin Hospital, Assistance Publique des hôpitaux de Paris (APHP), Université de Paris, Paris, France.
Christophe RousseauCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Jean-François LlitjosCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Sylvia SanquerMetabolic and Proteomic Biochemistry Department, Necker-Enfants malades Hospital, Université de Paris, Paris, France.
Jean-Paul MiraCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Frédéric PèneCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Julie ToubianaCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Jean-Daniel ChicheCochin Institute, Department of Infection, Immunity and Inflammation, Inserm U1016, Paris Descartes Sorbonne Paris Cité University UMR-S1016, Centre National de la Recherche Scientifique (CNRS) UMR 8104, Paris, France.
Sorbonne Paris Cité · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRHôpital Cochin · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulators of TLRs signaling pathways play an important role in the control of the pro-inflammatory response that contributes to sepsis-induced tissue injury. Mycophenolate mofetil, an immunosuppressive drug inhibiting lymphocyte proliferation, has been reported to be a regulator of TLRs signaling pathways. Whether MMF used at infra-immunosuppressive doses has an impact on survival and on innate immune response in sepsis is unknown. C57BL/6J mice were infected intraperitoneally with 10

Indexed as

BacteremiaSepsisStaphylococcal InfectionsAnimalsCytokinesDisease Models, AnimalImmunosuppressive AgentsMacrophages, PeritonealMiceMice, Inbred C57BLMycophenolic AcidStaphylococcus aureusToll-Like Receptor 4CytokinesImmunosuppressive AgentsMycophenolic AcidToll-Like Receptor 4innate immunitymacrophagesmycophenolate mofetilNF-κBphagocytosissepsisstaphylococcus aureustoll-like receptor 4

Identifiers

PMID35936013
PMCPMC9351454
OpenAlexW4285793221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.